Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| Switzerland | CHF | Delayed | ||
| Switzerland | CHF | Delayed | ||
| BATS Europe | CHF | Delayed | ||
| BATS Europe | CHF | Delayed | ||
| OTC Markets | USD | Delayed | ||
| OTC Markets | USD | Delayed | ||
| London | CHF | Real-time | ||
| London | CHF | Real-time | ||
| Mexico | MXN | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Frankfurt | EUR | Delayed |
Shares of Roxgold Inc. (CVE:ROG) crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of C$1.33 and traded as low as C$1.31....
UAA, PFE and CAR all rose following the release of their quarterly results. Earnings news sent GNRC lower. ROG soared on deal to be acquired by DD.
By Farah Master HONG KONG (Reuters) - If investors in China's biotech industry needed one more sign that the sector is coming of age, then a major licensing deal RemeGen Co Ltd...
Roche maintains a healthy balance sheet with $13.9 billion in cash and investments and $12.5 billion in long-term debt as of 12/31/2020.
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women’s health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. The company has collaboration with Gilead Sciences, Inc. for COVID-19; a license and collaboration agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza, as well as SemaThera Inc. to develop biologicals for the treatment of diabetic retinopathy and other ischemic retinal diseases; and has collaboration with Affimed N.V to study AFM24 in combination with PD-L1 checkpoint inhibitor in EGFR expressing solid tumors, as well as with Surface Oncology, Inc. to evaluate SRF388. It also has a clinical collaboration with Carrick Therapeutics, Ltd. to evaluate a novel combination of Carrick’s samuraciclib and its giredestrant in CDK4/6i resistant HR+, HER2- metastatic breast cancer; a collaboration with Zur Rose Group AG to empower people with diabetes and their caregivers in their daily therapy management; and a research collaboration and license agreement with Venatorx Pharmaceuticals, Inc. to discover, characterize, and develop new small molecule inhibitors of the Penicillin Binding Proteins in Gram-negative bacteria focused on agents active against carbapenem-resistant Enterobacterales. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Strong Buy | Strong Buy | Buy |
| Technical Indicators | Buy | Strong Buy | Strong Buy | Buy | Strong Buy |
| Summary | Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 332.90 | 338.10 | 330.25 | +7.45 | +2.29% | 36.78M | London | |||
| 2,394.00 | 2,437.00 | 2,367.00 | +43.0 | +1.83% | 390.39K | London | |||
| 0.1075 | 0.00 | 0.00 | 0.0000 | 0.00% | 54.65M | London | |||
| 11,755.00 | 11,780.00 | 11,540.00 | +290.0 | +2.53% | 452.35K | London | |||
| 2,225.00 | 2,245.00 | 2,170.00 | +30.00 | +1.37% | 139.61K | London | |||
| 1.85 | 1.85 | 1.74 | +0.400 | +27.59% | 77.56M | London | |||
| 66.00 | 68.00 | 64.80 | +2.40 | +3.77% | 32.73K | London | |||
| 215.60 | 217.30 | 212.90 | +3.00 | +1.41% | 10.42M | London | |||
| 2,358.00 | 2,360.00 | 2,276.00 | +58.0 | +2.52% | 111.67K | London | |||
| 461.40 | 468.00 | 451.00 | +3.40 | +0.74% | 1.93M | London | |||
| 111.06 | 112.62 | 107.44 | +1.72 | +1.57% | 66.88M | London | |||
| 8,314.00 | 8,373.00 | 8,232.00 | +38.0 | +0.46% | 1.90M | London | |||
| 126.14 | 127.94 | 123.28 | +3.64 | +2.97% | 37.35M | London | |||
| 4,691.50 | 4,781.50 | 4,618.50 | +79.5 | +1.72% | 4.11M | London | |||
| 1,040.00 | 1,050.00 | 975.80 | +63.80 | +6.54% | 794.39K | London |